Summary
Thermo Fisher Scientific Inc. reported solid financial performance for the fiscal year ended December 31, 2025, with revenues reaching $44.56 billion, a 4% increase compared to the previous year. This growth was primarily driven by strong demand in the pharmaceutical and biotechnology sectors, although a slowdown in COVID-19 related product and service demand partially offset this. The company experienced robust productivity improvements across its segments, particularly in Laboratory Products and Biopharma Services and Life Sciences Solutions, leading to an increase in both GAAP operating income margin (17.4%) and adjusted operating income margin (22.7%). Strategic acquisitions in 2025, including Olink Holding AB and a filtration and separation business, are expected to enhance Thermo Fisher's capabilities and market position, particularly in high-growth areas like proteomics and bioproduction. While the company faces headwinds such as macroeconomic uncertainties impacting academic and government markets and increased costs due to inflation and tariffs, its diversified business model and focus on innovation position it well for continued growth. The company's financial position remains strong, supported by significant free cash flow generation and a substantial cash balance, enabling ongoing investments in R&D, strategic acquisitions, and shareholder returns.
Financial Highlights
55 data points| Revenue | $44.56B |
| R&D Expenses | $1.40B |
| SG&A Expenses | $8.73B |
| Operating Expenses | $36.81B |
| Operating Income | $7.75B |
| Net Income | $6.72B |
| EPS (Basic) | $17.77 |
| EPS (Diluted) | $17.74 |
| Shares Outstanding (Basic) | 377.00M |
| Shares Outstanding (Diluted) | 378.00M |
Key Highlights
- 1Revenues increased by 4% to $44.56 billion in 2025, driven by pharma and biotech demand, despite a reduction in COVID-19 related product sales.
- 2GAAP operating income margin improved to 17.4% and adjusted operating income margin to 22.7%, reflecting strong productivity gains.
- 3The company completed strategic acquisitions in 2025, including Olink Holding AB (Life Sciences Solutions) and a filtration and separation business, to enhance its market offerings.
- 4Laboratory Products and Biopharma Services and Life Sciences Solutions segments showed strong organic revenue growth, contributing significantly to the company's performance.
- 5Despite some market softness in academic/government sectors and increased costs (tariffs, inflation), the company generated substantial free cash flow of $6.34 billion.
- 6Thermo Fisher ended the year with a strong liquidity position, holding $9.85 billion in cash and cash equivalents.